Opinion
Video
Overview and benefits of port delivery device with ranibizumab
Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides continuous medication delivery for 6 months, offering patients a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels.
Video content above is prompted by the following:
- Can you provide an overview of the port delivery device with ranibizumab approved for treating neovascular AMD?
- How does the device function?
- What are the benefits of using the port delivery device with ranibizumab?
- Certainty of 6 months of continuous anti-VEGF delivery
- Patients in clinical trials prefer PDS over intravitreal injections
Related Videos
Related Content
